XTRA:SRT3Life Sciences
Evaluating Sartorius (XTRA:SRT3) Valuation As Earnings And DCF Send Mixed Signals
Recent share performance and business snapshot
Sartorius (XTRA:SRT3) has stayed in focus after a period of weaker share performance, with the stock down over the past week, month, past 3 months and year to date, alongside reported annual revenue and net income growth.
The company reports revenue of €3.6b and net income of €162.6m, with operations spanning bioprocess solutions and lab products. Its market value stands at about €13.2b based on the latest closing share price of €211.40.
See our...